Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02117934 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
A Phase 3 study of Healthy, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,374
- Enrollment target
- 20
- Study locations
NCT02117934 is a Phase 3 study of Healthy that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 8,374 participants, above the 640-participant average among 1,090 other Healthy trials with a reported enrollment target (1208% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02117934, a Phase 3 study of Healthy, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,374 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
Conditions Studied
Interventions
- BIOLOGICAL Engerix-B
- BIOLOGICAL HEPLISAV
Study Locations (20)
Arizona
- Clinical Research Advantage, Inc. - Chandler
- Radiant Research - Chandler
- Clinical Research Advantage, Inc. - Glendale
- Clinical Research Advantage, Inc. - Mesa
- Clinical Research Advantage, Inc. - Mesa
- Clinical Research Advantage, Inc. - Phoenix
- Clinical Research Advantage, Inc. - Phoenix
- Clinical Research Advantage, Inc. - Phoenix
- Radiant Research - Scottsdale
- Clinical Research Advantage, Inc. - Tempe
- Radiant Research - Tucson
- Clinical Research Advantage, Inc. - Tucson
Colorado
- Clinical Research Advantage, Inc. - Centennial
- Clinical Research Advantage, Inc. - Colorado Springs
- Radiant Research - Denver
California
- Radiant Research - Santa Rosa
- Clinical Research Advantage, Inc. - Vista
Alabama
- Clinical Research Advantage, Inc. - Birmingham
Florida
- Radiant Research - Pinellas Park
Georgia
- Radiant Research - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,374 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02117934
The ClinicalTrials.gov registry entry for NCT02117934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,374 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 640-participant average among 1,090 other Healthy trials with a reported enrollment target (1208% higher). The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Engerix-B is the first listed.
NCT02117934 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT02117934 about?
NCT02117934 is a clinical study titled "Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine". The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
What is the current status of trial NCT02117934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,374 participants. The study started on 2014-04. Estimated completion is 2015-10.
What conditions does trial NCT02117934 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02117934?
The interventions under investigation include: Engerix-B (BIOLOGICAL), HEPLISAV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02117934?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02117934 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.